Barclays reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note published on Tuesday, February 5th.
A number of other research firms have also recently weighed in on AZN. HSBC set a GBX 4,860 ($63.50) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Monday, November 12th. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Friday, November 16th. JPMorgan Chase & Co. set a GBX 6,900 ($90.16) target price on shares of AstraZeneca and gave the stock a buy rating in a research note on Friday, November 16th. Kepler Capital Markets reaffirmed a buy rating and set a GBX 6,100 ($79.71) target price on shares of AstraZeneca in a research note on Thursday, November 22nd. Finally, Investec cut shares of AstraZeneca to a hold rating and boosted their target price for the stock from GBX 5,500 ($71.87) to GBX 6,300 ($82.32) in a research note on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of GBX 6,236.20 ($81.49).
LON:AZN traded up GBX 47 ($0.61) during mid-day trading on Tuesday, reaching GBX 6,186 ($80.83). The stock had a trading volume of 2,191,759 shares, compared to its average volume of 2,310,000. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).
The business also recently disclosed a dividend, which will be paid on Wednesday, March 27th. Stockholders of record on Thursday, February 28th will be issued a dividend of GBX 146.80 ($1.92) per share. The ex-dividend date is Thursday, February 28th. This represents a dividend yield of 2.57%. This is a positive change from AstraZeneca’s previous dividend of $68.40.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.